Squibb Company (NYSE:BMY) announced today that the U.S. Food and
Drug Administration (FDA) has approved the company's biologics
manufacturing facility in Devens, Massachusetts for commercial
production of ORENCIA®
The Devens facility, a state-of-the-art bulk biologics manufacturing
facility, employs roughly 300 scientists, engineers, bioprocess
operators, quality specialists and other skilled workers.
"The approval of our Devens site is an important milestone for
Bristol-Myers Squibb as part of our strategic focus on delivering
innovative biologic medicines for patients with serious disease," said Lou
Schmukler, president, Global Manufacturing & Supply, Bristol-Myers
Squibb. "The increased manufacturing capacity from the Devens site will
support market demand for ORENCIA and positions us well for future
production of additional biologic medicines."
Bristol-Myers Squibb currently manufactures its biologic medicines in a
company-owned facility in Syracuse, NY and through third party
suppliers, and finishes and packages them in Manati, Puerto Rico. The
Syracuse site will remain a key component of the company's biologics
strategy and will serve as a center of excellence in process development
and early product launch for the company's biologic medicines.
"Bristol-Myers Squibb is committed to building a strong manufacturing
capability to support our growing biologics portfolio, and Devens is a
key component of this strategy," said Peter Moesta, senior vice
president, Biologics Manufacturing and Process Development.